This prospective phase II study was undertaken to evaluate the efficacy and toxicity of early intensive therapy followed by purged autologous bone marrow transplantation (ABMT) in patients with follicular lymphoma with high tumor burden. All patients received the VCAP regimen (vindesine, cyclophosphamide, doxorubicin and prednisone) as conventional chemotherapy and DHAP as second-line therapy. Twenty-nine consecutive patients were included in the study. Twentyseven patients were grafted, seven in first complete remission (CR) and 20 in first partial remission (PR). Preparative therapy consisted of cyclophosphamide and total body irradiation (TBI) in all the patients. With a median follow-up of 6 years, the actuarial overall survival is 64% and the actuarial event-free survival is 55%. Two treatment-related early deaths were observed. Eleven patients were informative for serial PCR analysis of minimal residual disease after ABMT: two relapsed, four remained disease-free with PCR positivity and five were disease-free with PCR negativity. These encouraging results lay the basis of future prospective randomized trials comparing autologous stem cell transplantation as front-line treatment with conventional chemotherapy for patients with bad prognostic factors. Bone Marrow Transplantation (2000) 26, 971-977.
in advanced-stage low-grade lymphoma. Conventional approaches have resulted in an average survival of 6-10 years in recent studies. 1, 2 For patients with poor prognostic features, ie the high-risk group in the International Prognostic Index (IPI), high tumor burden, patients with primary refractory disease or partial remission after front-line therapy, the median survival is significantly shorter.
Attention has recently been focused on the use of very intensive therapy supported by autologous stem cell transplantation (ASCT) for patients with intermediate and highgrade histology treated in relapse 3 or in first-line therapy. [4] [5] There is considerably less experience with transplantation for relapsing patients with low-grade NHL: the results in heterogeneous groups suggest that this approach can achieve 25 to 50% long-term survival, according to the series. [6] [7] [8] [9] [10] [11] [12] [13] [14] Very few findings have been published about the value of ASCT as first-line therapy for poor-risk patients with low-grade NHL. [15] [16] [17] [18] It has been demonstrated using molecular biology techniques that minimal residual disease may be present in the bone marrow and peripheral blood of patients with follicular lymphoma who are otherwise considered to be in complete remission (CR). 19 As reported by Gribben et al, 20 bone marrow purging apparently has an impact on disease-free survival (DFS) of patients grafted for low-grade NHL. Patients with negative autografts after purging for t(14;18) using polymerase chain reaction (PCR) had significantly better disease-free survival compared with those transplanted with PCR-positive bone marrow.
We present the long-term results of a phase II pilot study of 29 patients with follicular NHL with bad prognostic factors according to the Groupe d'Etude des Lymphomes Folliculaires (GELF) criteria 21 who received myeloablative therapy and purged bone marrow stem cells as first-line therapy. Minimal residual disease (MRD) was evaluated in 12 patients who were PCR-positive on diagnosis: (1) to evaluate the possibility of achieving PCR negativity after conventional chemotherapy; (2) to evaluate the capacity of BM purging to obtain PCR-negative transplants; (3) to evaluate the clinical relevance of PCR analysis after autografting.
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Materials and methods
Selection of patients and treatment protocol
Patients were eligible for entrance into this phase II trial if they were aged 60 years or less, had previously untreated follicular lymphoma according to Working Formulation (WF) criteria including: follicular small cleaved cell (WF-B), follicular mixed small cleaved and large cell (WF-C) and follicular large cell lymphoma (WF-D). Patients were required to have a high tumor burden according to the GELF classification, 21 ie including one of the following criteria: nodal or extranodal disease of more than 7 cm, presence of B symptoms, considerable splenomegaly, pleural effusion or ascites, complications such as compression, increased LDH or ␤ 2 microglobulin levels. Informed consent was obtained from all patients.
All patients received the VCAP regimen as first-line therapy combining vindesine 3 mg/m 2 on day 1, cyclophosphamide 1500 mg/m 2 on day 2, doxorubicin 80 mg/m 2 on day 2 and prednisolone 50 mg/m 2 /day on days 1 to 5. After three cycles every 3 weeks, patients in complete remission (CR) or in partial remission (PR) went on to bone marrow harvesting. Patients with minimal response received two to three courses of DHAP combining cisplatine 100 mg/m 2 on day 1, cytarabine 4 g/m 2 on day 2 and dexamethasone 40 mg/m 2 on days 1 to 4 as second-line therapy. If a partial or a complete response were obtained after DHAP, bone marrow was harvested. After BM harvesting and before the conditioning regimen, patients received one or two courses of IMVP16, which combines ifosfamide 1.5 g/m 2 on days 1 to 3, VP16 100 mg/m 2 on days 1 and 3 and methotrexate 30 mg/m 2 on days 1 and 10. Preparative therapy consisted of cyclophosphamide (60 mg/kg body weight) infused on each of 2 consecutive days of radiotherapy. Total body irradiation (TBI) was administered in fractionated doses (200 cGy) twice daily on 3 consecutive days in all patients.
BM collection, purging and cryopreservation procedures
BM collection was performed in patients in CR or PR after VCAP or DHAP regimen. Three types of immunological purging to reduce MRD in the transplants were performed according to the center:immunological purging with complement in 20 patients, immunological purging with immunobeads in five patients and CD34 positive cell selection in two patients.
Immunological purging technique with complement: BM cells were treated with three monoclonal antibodies (MoAb): CD19/B64, CD20/B B6, CD10/B E3) (Innotherapy, Besançon, France) and newborn rabbit complement (CRTS Besançon, France).
The MNC obtained after Ficoll centrifugation were washed twice and adjusted with 4% human albumin to a concentration of 2 × 10 7 cells/ml. A mixture of CD19 and CD20 (10 g of each for 1 × 10 7 cells) and CD10 (5 g for 1 × 10 7 cells) was added and incubated for 30 min at +4°C, with gentle tilting. Then three cycles were completed with rabbit complement.
For each cycle, 1 vol complement was added to 2 vol cells and after incubation for 30 min at 37°C, the mixture was centrifuged, the supernatant discarded and the cells resuspended in 4%. human albumin.
Immunomagnetic purging technique:
The procedure was completed using the Max SEP TM system (Baxter Immunotherapy Division, Germany) and five Moab (anti CD19, CD20, CD22, CD23, CD37). After Ficoll, the MNC were incubated with 1 mg of each MoAb per 1 × 10 8 total nucleated cells for 30 min at +4°C. Excess MoAb was removed by washing cells twice in cold buffer. Immunomagnetic sheep anti-mouse beads were then added to obtain a ratio of two beads per cell and incubated for 30 min at +4°C. Magnetic separation was performed on Max SEP, and the negative MNC collected were remixed once more with beads.
CD34-positive selection of BM cells:
Selection was performed according to the manufacturer's instructions (Ceprate SC Stem Cell Concentration System, Cellpro, Bothell, WA, USA). Washed BM cells were incubated with 20 g/ml of biotinylated anti-CD34 monoclonal antibody. The treated cells were washed with PBS (phosphate-buffered saline without Ca ++ or Mg ++ (Cell Pro, Bothell, WA, USA)) to remove unbound antibodies and processed through the avidin-coated column of the Ceprate SC apparatus.
The cryopreserved marrow cells were rapidly thawed and reinfused within 48 h of the completion of chemotherapy.
Evaluation
All patients were evaluated before treatment by physical examination, blood chemistry profile, complete blood count, chest X-ray, thoraco-abdominal CT scan and bone marrow biopsy. Follow-up restaging was performed after VCAP and, if necessary, DHAP chemotherapy, every 6 months after transplantation for 2 years post ABMT and yearly thereafter. CR was defined as the disappearance of all measurable and evaluable disease. PR was defined as Ͼ50% reduction in measurable lesions without the appearance of new lesions or by persistence of BM infiltration.
PCR amplification of Bcl-2/IgH translocation
Blood and bone marrow cells were obtained from patients and healthy donors after informed consent. Mononuclear cells were separated by Ficoll-Hypaque density centrifugation (Seromed, Biochrom KG, Berlin, Germany).
DNA was obtained after proteinase K digestion (Merck, Darmstadt, Germany), phenol-chloroform extraction and ethanol precipitation or by the salting out procedure as previously described.
The major breakpoint region of bcl-2 (MBR) was subjected to nested PCR. The primers used to amplify the bcl2-JH translocation were those previously described by Gribben et al. 20 The first amplification was performed with 250 ng DNA in a total volume of 50 l containing 150 mol/l dNTPs (Amersham Pharmacia Biotech, Saclay, France), I × Taq buffer (10 mmol/l Tris-HCl pH 8.3, 50 mmol/l KCl, 1 mmol/l MgCl 2 ), 125 ng of each primer and 1 U of Taq Polymerase (Life Technologies, Cergy-Pontoise, France). The second amplification was performed on 1 l of the first PCR product in the same reaction mixture but for dNTPs (100 mol/l) and the internal primer (50 ng). The primers used were as follows: 5′-CAG CCT TGA AAC ATT GAT GG-3′ and 5′-TAT GGT GGT TTG ACC TTT AG-3′ as bcl2 primers, 5′-ACC TGA GGA GAC GGT GAC C-3′ and 5′-ACC AGG GTC CCT TGG CCC CA as JH consensus primers, for the first and nested PCR, respectively. The amplification mixture was incubated for 7 min for denaturation at 94°C. The DNA template was amplified for 35 cycles at 94°C for 45 s then at 60°C for the first or 58°C for the nested PCR for 45 s and at 72°C for 45 s and finally incubated for a final elongation step for 7 min at 72°C in a thermal cycler 2400 (Perkin Elmer, Applied Biosystem, Courtaboeuf, France). Ten l of the second amplification products were electrophoresed through a 6% acrymalide gel (BioProbe, Paris, France) stained with ethidium bromide and visualized by UV light. If necessary, the specificity of the PCR products was verified by hybridization with a bcl-2 oligoprobe (5′-GCC TGT TTC AAC GAC CC-3′) or sequencing.
The absence of amplication of the bcl2/JH hybrid DNA fragment was ratified if the amplification of a 553 bp fragment of the ␤-actin gene confirmed the characteristics of the amplified DNA sample. A negative result was established only if the 10 5 dilution in normal DNA of the control cell line was positive. Positive results were validated only if the negative controls (healthy donor and tube without DNA) were unamplified.
Statistical methods
An event was defined as progression, relapse of disease or death in remission. Event-free survival (EFS) was calculated from the date of the beginning of treatment until the occurrence of the event using the Kaplan and Meier methods. 22 Overall survival time was defined as the time from inclusion until death from any cause or until last follow-up evaluation for patients who were still alive.
Results
Patient characteristics
Twenty-nine patients (median age 42 years; range 28-60) with previously untreated high tumor burden follicular lymphomas were included in this study between December 1991 and January 1994. At diagnosis, nine of the 29 patients had follicular small cleaved cell (FSC), 18 had follicular mixed small cleaved and large cell lymphoma (FM) and two had follicular large cell lymphoma (FLC).
Patient characteristics are summarized in Table 1 . All but one were stage III-IV. Sixteen patients had an abdominal mass greater than 10 cm.
Response to induction therapy
After the three courses of VCAP, six patients were in CR, 20 patients in PR, two had stable disease and one patient Bone Marrow Transplantation had progressed. Three patients received two to three courses of the DHAP regimen and 15 patients received one to three courses of IMVP16. Twenty-seven patients were grafted, seven in CR and 20 in PR. Two patients were not grafted because of refusal (one patient) or progressive disease (one patient). These results suggest that this type of first-line chemotherapy can induce sufficient tumor response to permit autologous stem cell transplantation in newly diagnosed FL with high tumor burden. 
In vitro treatment of bone marrow
Clinical toxicity and hematologic recovery after autologous bone marrow transplantation
Of the 27 patients who were transplanted, there were two treatment-related early deaths from septicemia (n = 1) and non-documented interstitial pneumonitis (n = 1). Eighteen patients received G-CSF after transplantation.
The median time to engraftment was 19 days for neutrophil recovery Ͼ0.5 × 10 9 /l (range 10-Ͼ90) and 25 days for Bone Marrow Transplantation platelet recovery Ͼ30 × 10 9 /l (range 14-Ͼ90). Only one patient had not engrafted 2 months after reinfusion of treated marrow and an untreated back-up marrow was used successfully.
Clinical outcome (Figure 1)
Nineteen patients remain alive with a median follow-up of 6 years. As noted earlier, there were two treatment-related early deaths and one patient with progression after induction therapy who died 14 months after beginning treatment. Nine patients relapsed after ABMT and seven of them have subsequently died (between 13 and 67 months after diagnosis).
The patient who refused ABMT relapsed 36 months after initial therapy and is still alive.
The actuarial overall survival (OS) is 64% (95% confidence interval = 53-74%; and the actuarial event-free survival 55% (95% confidence interval = 43-66%). At this time medians for OS and EFS have not yet been reached.
PCR analysis (Figure 2)
Blood and bone marrow samples were available at the time of initial diagnosis in 23/29 patients. Eleven were negative for MBR. Twelve patients were therefore available for sequential PCR analysis.
After induction chemotherapy, only one patient was negative for the t(14;18) in blood and BM. After in vitro treatment, two BM samples became PCR-negative and nine of 11 remained PCR-positive. The technique used for BM purging for the two patients who became negative was immunological purging with complement.
Twelve patients were informative for serial analysis of minimal residual disease after ABMT. One year after ABMT, six were PCR-positive and five PCR-negative. Of the six patients who were PCR-positive, one relapsed and five remained in CR, two with subsequent negativization of the PCR. Of the five patients who were PCR-negative one year after ABMT, 1 relapsed after becoming PCRpositive again and four remained disease-free, three without PCR-detectable disease. 
Discussion
In this report, we present the results of 29 patients entered in a phase II study testing the value of purged bone marrow transplantation after high-dose conventional chemotherapy in newly diagnosed follicular lymphoma with the longest follow-up yet published. We found an overall survival of 64% and an event-free survival of 53% at 8 years. This preliminary trial shows that the majority of patients can achieve partial remission after conventional chemotherapy and could be grafted.
Very few studies have reported the results of autologous stem cell transplantation as first-line therapy of follicular lymphomas. [15] [16] [17] [18] Ten patients autografted for consolidation of early remission were published by Fouillard et al. 15 Marrows were purged in vitro by mafosfamide at individually adjusted levels. Eight patients remained in unmaintained CR 15 to 43 months after ABMT at the time of publication. Haas et al 17 reported 28 patients grafted with unpurged peripheral blood stem cells and conditioned by total body irradiation and cyclophosphamide. With a median followup of 15 months, 27 out of the 28 patients grafted in first remission were alive without relapse. Corradini et al 18 reported 21 follicular lymphomas (eight with transformed histology) who were grafted after conventional chemotherapy, peripheral blood stem cell harvesting (or BM harvesting if PBSC collection failed) and a conditioning regimen combining mitoxantrone and high-dose melphalan; 16 of the 21 patients with follicular lymphoma were autografted and evaluable for clinical results: 14 patients (80%) were alive in continuous CR at a median follow-up of 19 months. In the largest series published by Freedman et al, 16 83 patients with previously untreated follicular lymphoma received CHOP induction; for patients in PR or CR, bone marrow was harvested and BM cells were purged with three monoclonal antibodies and complement. With a median follow-up of 45 months, disease-free survival and overall survival were estimated to be 63% and 89% at 3 years.
Our results appear relatively comparable whilst all the patients in our study had poor prognostic factors according to the GELF criteria 21 and were probably a subgroup of patients with a worse prognosis than the patients included in other studies. The relapse rate that we observed might have been related to the fact that most patients had a high tumor burden and only seven were in CR at the time of BMT. A combination of conditioning regimens using only pharmacological drugs and involving field radiotherapy could perhaps improve these results.
Our results appear better in terms of EFS but comparable in terms of OS if we compare them with the best results of conventional chemotherapy yet published. Solal-Celigny et al 21 recently reported the final analysis of a randomized study where 123 patients with the same inclusion criteria were treated with a combination of cyclophosphamide, doxorubicin, teniposide and prednisone (CHVP) and interferon; with a 6 year median follow-up, the median progression-free survival was 2.9 years and the 5 year overall survival was 70.5%.
The timing of autologous stem cell transplantation as first-line or second-line therapy of high-risk follicular lym- phoma remains questionable. We recently reported the results for patients with high tumor burden grafted as firstline therapy or in relapse. 23 Apostolidis et al 24 evaluated the survival pattern of patients with FC following recurrence after myeloablative therapy and showed that survival after recurrence was similar to that of a historical control group who received conventional therapy as initial treatment.
Caution about possible benefits is also demanded by the toxicity of the treatment. Two toxic deaths occurred in our study, but no case of myelodysplasia has occurred to date. These early and late toxicities have to be taken into account in the therapeutic approaches to indolent lymphoma.
A major issue when using autologous BM or PBSC is whether reinfused tumor cells may contribute to relapse. No randomized study comparing purged vs unpurged BMT in the treatment of FL has been published to date. The European Marrow and Blood Transplant Registry (EBMTR) 25 has reported that the 5 year OS of patients who received purged (monoclonal antibody or cyclophosphamide) marrow was higher than that of those receiving untreated BM (54% vs 48%) with no difference in PFS (44% in both arms).
The Dana Farber Cancer Institute has examined the impact of the presence of residual neoplastic cells in the autograft upon DFS. 13, 20 In the more recent publication, 13 patients whose BM was negative by PCR for bcl2/IgH rearrangement after purging experienced longer freedom from recurrence than those whose BM remained PCRpositive: the 8 year FFR was 83% for PCR − and 14% for PCR + patients. Although the purging of harvested stem cells appears important, it appears that the type of stem cells (PBSC/BM) and the purging technique could play a role. McQuaker et al 26 and Voso et al 27 showed the lack of t(14;18) PCRpositive cells in highly purified CD34
+ peripheral blood stem cells. Although negative selection of BM stem cells
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with monoclonal antibodies and complement or immunomagnetic beads seems unable to eradicate the t(14;18)-bearing clone in most patients, 28 ,29 the technique of negative purging appears important. Gribben et al 30 showed that the addition of a fourth monoclonal antibody increases the efficiency of complement-mediated lysis and that immunomagnetic bead depletion is superior to complementmediated purging.
Some studies 31, 32 have also evaluated the prognostic value of molecular monitoring of minimal residual disease after PB or BM stem cell transplantation as first-or secondline therapy. All these studies confirmed the prognostic value of bcl2 PCR negativity post transplantation. These results were recently confirmed by Lopez-Guillermo et al 33 who showed that patients treated with conventional chemotherapy achieved a molecular response during the first year of treatment and sustained it, had better failure-free survival than those who either reverted back to positive PCR or who never achieved a molecular response. In our trial, we confirmed the prognostic value of PCR negativity post transplantation and also the possibility of very long complete remission in some patients who remain PCR-positive, as previously described in stage I-II localized FL treated by radiotherapy alone. 34 In conclusion, this phase II trial appears encouraging and large phase III trials are therefore needed to show the superiority of purged or unpurged autologous stem cell transplantation in comparison with conventional chemotherapy in the treatment of advanced stage of FL with poor prognosis.
